Blog
Retatrutide Side Effects by Dose: How Often, How Long and How Serious
Most people who took retatrutide in its trials reported a side effect at some point. So did most people on placebo. TRIUMPH-1 followed 2,339 adults with obesity for 80 weeks, and 80.7% of its placebo group logged an adverse event, against 87% to 89.2% of those on the drug.
The difference between those numbers is the real side effect profile, and it is short: a queasy, slower stomach, a tingling skin sensation the older drugs rarely cause, and a few extra heartbeats a minute in the first months. All of it grows with the dose and bunches up in the weeks the dose climbs.
Retatrutide is Eli Lilly’s once-weekly peptide aimed at three hormone receptors at once, GLP-1, GIP and glucagon, and the guide to what retatrutide is covers how that works.
Retatrutide side effects by dose
At 4mg a week, about one person in seven gets nausea they would not have had on placebo. At 12mg it is more than one in four. TRIUMPH-1 logged nausea in 14.8% of its placebo group, then 28.6%, 38.4% and 42.4% of the 4, 9 and 12mg groups (Jastreboff, New England Journal of Medicine, 2026). The difference, not the raw figure, is what the drug adds.
The other stomach effects move at different speeds. Vomiting is the steepest: 10.6% on 4mg, more than doubling to 25.3% on 12mg, against 4.8% on placebo. Diarrhea climbed from 25.2% on 4mg to 34.1% on 9mg, then held at 32.0% on 12mg (13.5% on placebo). Constipation barely moved with dose, 23.8% to 26.1% against 10.9%, so someone on the lowest dose is about as likely to notice it as someone on the highest.
Most cases were mild or moderate. Smaller appetite is the intended effect, yet in the Phase 2 trial 29% of the 12mg group still listed it as a side effect, against 9% on placebo, and 10% listed fatigue, against 4% (Jastreboff, New England Journal of Medicine, 2023).

When retatrutide side effects start and when they fade
They start with the first doses or a dose increase, crowd into the months the dose is climbing and ease once it holds.
The pace of the climb counts for more than the final dose. The Phase 2 obesity trial took two groups to the same 8mg. Starting from 2mg, one reported nausea at 17% and vomiting at 6%; starting from 4mg, the other reported 60% and 26% (Jastreboff, New England Journal of Medicine, 2023). Every Phase 3 trial since has kept the 2mg start and added a step every four weeks, so 12mg arrives at week 17. The retatrutide dosage chart lays out each step.
Few people quit over it. In TRIUMPH-1, stomach side effects made 2.2% to 4.6% of the retatrutide groups stop for good, against 1.2% on placebo (Lilly, June 6, 2026). The knee trials let investigators step the dose back for stomach trouble, poor eating or too much weight lost, and 89.9% of the 12mg group in TRIUMPH-4 still reached 12mg.
After the last injection they wind down as the drug clears, a little more than half of it each week on a half-life of about six days. The retatrutide half-life guide covers how long it stays measurable, and Can You Stop Retatrutide? covers what happens to weight.
Retatrutide skin side effects: pins and needles
Dysesthesia, a tingling, prickling or burning feeling in skin that looks normal, is the side effect retatrutide adds to its class. TRIUMPH-1 counted it in 0.9% of the placebo group, 5.1% at 4mg and about one in eight at both 9mg (12.3%) and 12mg (12.5%), so the last step barely changed it.
The starting dose shaped it too. In Phase 2, skin sensation events hit 3% of the 8mg group that began at 2mg and 14% of the 8mg group that began at 4mg, with 13% on 12mg and 1% on placebo. None were severe or serious, and none came with a rash or any other visible change to the skin.
TRIUMPH-4, a 68-week trial in adults with knee arthritis, holds the top rate so far: 20.9% of its 12mg group, mostly mild and rarely a reason to stop. People with type 2 diabetes reported it less, 4% to 7% against 1% (Bellido, The Lancet, 2026). On tirzepatide the same complaint shows up in well under 1 in 100, which is why it reads as retatrutide’s own.

Retatrutide heart rate and blood pressure
Resting heart rate goes up by a few beats a minute, most in the first six months, then drifts back down while treatment continues. In Phase 2 the rise grew with dose, topped out at week 24 and had eased by weeks 36 and 48, about the size seen with GLP-1 drugs (Jastreboff, New England Journal of Medicine, 2023). Glucagon and GLP-1 both nudge the heart to beat faster, and retatrutide acts on both.
Rhythm events of the kind that start in the upper chambers or the heart’s wiring were logged in 6% of Phase 2 participants on retatrutide and 3% on placebo, all mild or moderate except one prolonged QT interval in someone also given ondansetron, an anti-nausea drug. In the two knee trials, severe or serious rhythm events stayed between 0% and 2.0% of each group, placebo included (Schnitzer, New England Journal of Medicine, 2026).
Blood pressure falls, which is mostly good news. By week 48 of Phase 2, 41% of participants in the 8mg groups and 30% in the 12mg group had come off at least one blood pressure medicine. The flip side is pressure dropping too low: 1%, 5% and 6% on 4, 9 and 12mg against under 1% on placebo in TRIUMPH-2 (Bellido, The Lancet, 2026). In TRIUMPH-1 it came up more often in people already taking blood pressure medicines.
Serious side effects of retatrutide
They are uncommon, and the gap to placebo is a few points. Serious adverse events, which in trial language means anything that put someone in hospital or worse, from any cause, came to 4% on retatrutide and 4% on placebo in Phase 2. In TRIUMPH-1 they ran 7.7% to 10.5% against 5.5%.
Gallbladder and pancreas
Fast weight loss raises gallstone risk whatever causes it. Phase 2 had three gallbladder events among 267 people on retatrutide and none among 70 on placebo, and one case of pancreatitis, on 12mg. Across the two knee trials, severe or serious gallbladder events ran at 0% to 0.7% per retatrutide group, against 0% and 1.4% on placebo, and two adjudicated pancreatitis cases came up, both on 9mg.
Liver and kidneys
The liver mostly gains. Brief rises in the liver enzyme ALT to three times normal showed up in 1% of Phase 2 participants, while average ALT and AST were flat or lower by week 48. Among those who began with a fatty liver, 12mg cleared 82.4% of the liver fat in 24 weeks (Sanyal, Nature Medicine, 2024). Kidney events ran at about 1% in both arms of Phase 2. In this class, kidney trouble tends to follow dehydration from days of vomiting or diarrhea.
Thyroid and cancer
The thyroid question comes from the class: drugs that act on GLP-1 caused thyroid C-cell tumors in rodents, a link not established in people. Phase 2 found no medullary thyroid cancer and no C-cell overgrowth, and Phase 3 left out anyone whose own or family history included that cancer. One thyroid cancer or C-cell finding was reported on 12mg across the two knee trials’ 725 participants on the drug.
Reta peptide side effects outside the trials
People using research-supply retatrutide describe a different mix. A 2026 study read the posts of 13,589 people describing their own use of non-approved retatrutide from March 2023 through 2025. Among the 7,823 who named a symptom, the most common complaint was more hunger (17.1%), then fatigue (15.2%), a lift in energy (12.4%), nausea (11.6%), poor sleep (6.1%) and a faster heartbeat (4.8%), with anxiety at 3.8% and headache at 3.0% (Sehgal, JAMA Network Open, 2026).
Next to posts about semaglutide and tirzepatide, retatrutide users wrote more about energy, sleep and pulse and less about nausea. Posts carry no placebo group and no dose check, and the authors named product and dose variability, stacking several peptides and mixing habits among the likely reasons.
Dose variability is the part a buyer controls, and it starts with knowing what the vial holds. Simms Research’s current retatrutide batch, tested July 16, 2026 by an independent ISO-certified lab, measured 10.68mg in vials labeled 10mg across three vials, at 99.611% purity; LC-MS confirmed the molecule and endotoxins passed. The trials’ own lesson applies too: a slow climb from 2mg kept nausea to a fraction of what a 4mg start produced.
Simms Research’s version is Retatrutide (GLP-3), in four vial sizes from 10mg to 60mg. The retatrutide lab results page lists the batch, and the retatrutide calculator turns any dose and mix into syringe units.

Retatrutide long-term side effects
The longest placebo-controlled data run 80 weeks, and the pattern held across them: stomach effects packed into the climb, heart rate topping out near week 24, skin sensation mostly clearing on treatment. Phase 3’s larger numbers added a few more urinary tract infections than placebo, nearly all in women; the guide to side effects of retatrutide for women covers them.
Who takes it changes the numbers more than time does. At 12mg against placebo, trial by trial:
| Trial | Weeks | Who took part | Skin sensation | Stopped over side effects |
|---|---|---|---|---|
| Phase 2 | 48 | Obesity | 13% vs 1% | 16% vs 0% |
| TRIUMPH-1 | 80 | Obesity | 12.5% vs 0.9% | 11.3% vs 4.9% |
| TRIUMPH-1 knee group | 80 | Obesity and knee arthritis | 15.3% vs 0.7% | 15.3% vs 6.2% |
| TRIUMPH-2 | 80 | Obesity and type 2 diabetes | 7% vs 1% | 8% vs 5% |
| TRIUMPH-4 | 68 | Obesity and knee arthritis | 20.9% vs 0.7% | 18.2% vs 4.0% |
TRIUMPH-4 ran highest on both counts and the diabetes trial lowest (Schnitzer, New England Journal of Medicine, 2026). Past week 80, 532 people in the TRIUMPH-1 extension kept taking it to week 104, and Lilly’s heart and kidney outcomes trial, sized at 10,000 adults, is due to finish in February 2029. The closest long-run reference is the class: semaglutide’s SELECT trial followed 17,604 adults for an average of 40 months and cut heart attacks, strokes and cardiovascular deaths by 20% (Lincoff, New England Journal of Medicine, 2023).
Is retatrutide safe?
On 80 weeks of trial data, yes at the doses tested, with a trade that grows with the dose. At 4mg, 4.1% stopped because of a side effect, under placebo’s 4.9%. At 12mg about one in nine did, the stomach being the most common reason, and serious events ran a few points above placebo. No one in the Phase 2 obesity trial had a clinically significant low blood sugar.
It is not approved for any use yet. Lilly expects to ask the FDA for approval early in 2027, and the guide to when retatrutide will be FDA approved tracks the steps. Next to approved drugs, the stomach rates run above those in the tirzepatide side effects guide, and the skin sensation is the one new item.
Frequently asked questions
Does retatrutide cause hair loss?
Phase 2 did not list it among its common side effects. In this drug class, hair loss is a temporary shed that trails rapid weight loss by a couple of months, and the hair returns. Does Tirzepatide Cause Hair Loss? covers the timeline, which carries over to retatrutide.
Does retatrutide affect mood or sleep?
Not in the trial record so far. Phase 2 logged one depression or suicidal-thought event, in the placebo group, and the two knee trials one severe or serious event, on 12mg. Outside trials, poor sleep is the more common complaint, named by 6.1% of users who listed a symptom in that 2026 study.
Does retatrutide have more side effects than tirzepatide?
Somewhat more nausea at the top dose, plus the skin sensation, for more weight lost. Zepbound’s weight loss trials logged nausea in 25% to 29% against 8% on placebo; retatrutide 12mg reached 42.4% against 14.8%. They come from separate trials, and retatrutide vs tirzepatide sets the two side by side.
Are retatrutide side effects different for men?
The list is the same. Men lost less weight than women on the same doses in Phase 2, and the extra urinary tract infections in Phase 3 fell almost entirely on women.